|Day Low/High||64.23 / 64.79|
|52 Wk Low/High||77.92 / 120.37|
Shares of the biopharmaceutical firm are lower by over 10% year-to-date.
A study of analyst recommendations at the major brokerages shows that Gilead Sciences, Inc. is the #56 broker analyst pick among those stocks screened by The Online Investor for strong stock buyback activity.
President Trump delivered some good news to tech giants and other corporations hoarding loads of cash abroad -- a 10% repatriation holiday is back on the table.
A roundup of Cramer's comments on stocks of interest to viewers.
With the Fed and the healthcare vote out of the way, markets will focus on earnings in the week ahead.
Doug Kass shares his thoughts on Facebook, Allergan and Apple.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Kevin Young CBE, Gilead's Chief Operating Officer, and Norbert W.
Stocks move mostly lower on Thursday after the House passes a bill to repeal and replace the Affordable Care Act.
Gilead's first-quarter conference call delivered another opportunity for analysts to ask management, 'Who are you going to buy and when?'
The central bank's faith in the economic recovery lifts some of the weight on Wall Street Wednesday. Stocks close mostly lower, though well off their lows.
Stocks hold mostly lower on Wednesday after the Federal Reserve's policy-making group decides to leave its federal funds rate unchanged.
Stock losses deepen on Wednesday morning after crude oil turns negative and a decision from the Federal Reserve looms.
Stock futures are lower on Wednesday morning after Apple posts weaker quarterly iPhone sales than analysts had anticipated.
Nearly anything associated with oil and gas drilling gets crushed.
Gilead also missed analysts' revenue expectations for the first quarter.
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company's Board of Directors has declared a cash dividend of $0.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter ended March 31, 2017.
U.S. stock futures point to a mixed start for Wall Street on Tuesday ahead of a meeting of the Federal Reserve and earnings from tech giant Apple.
European stocks posted modest gains at the open of trading Tuesday as investors returned from a May holiday weekend to stronger U.S. tech sector earnings and improving geopolitical sentiment.
European stocks are set to open higher Tuesday as investors return from a May holiday weekend to stronger U.S. tech sector earnings and improving geopolitical sentiment.
May kicks off with a busy first week filled with earnings, monetary policy and a snapshot of the health of the economy.
Doug Kass shares his thoughts on Facebook, Allergan and Eli Lilly.
Apple isn't the biggest winner from Trump's plans for a tax holiday. These three stocks are...
Apple isn't the biggest winner from Trump's plans for a tax holiday. These three stocks are. ...
Biotech investors should keep a close eye on the progress in this huge potential market.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from two Phase 2 studies evaluating Harvoni ® (ledipasvir 90 mg/sofosbuvir 400 mg, LDV/SOF) tablets in chronic hepatitis C virus (HCV)-infected patient...